HIV Window Period | STD TESTING SINGAPORE™
HIV Window Period | STD TESTING SINGAPORE™ @stdtestingsingapore_com: HIV (human immunodeficiency virus) window period, Singapore. Private & confidential service.
Come to sunny Singapore to have your testing and treatment. Singapore Ministry of Health registered general practice (GP) clinic:
| SHIM CLINIC|
STD TESTING SINGAPORE™
168 Bedok South Avenue 3 #01-473
Tel: (+65) 6446 7446
Fax: (+65) 6449 7446
24hr Answering Tel: (+65) 6333 5550
Web: HIV Window Period | STD TESTING SINGAPORE™
| Opening Hours |
Monday to Friday: 9 am to 3 pm, 7 pm to 11 pm
Saturday & Sunday: 7 pm to 11 pm
Public Holidays: Closed
Last registration: one hour before closing time.
Walk-in clinic. Appointments not required.
Bring NRIC, Work Pass or Passport for registration.
Table of Contents HIV window period is the time from HIV infection until a HIV Test can detect any change. Within the HIV window period, the HIV Test would be negative. During this period, the HIV viral load is extremely high, thus making the person highly infectious.
References HIV is the abbreviation for the human immunodeficiency virus, which causes the acquired immunodeficiency syndrome
- 4 weeks after exposure, a negative 4th generation HIV ELISA Test "is very reassuring / highly likely to exclude HIV infection."
- 12 weeks after exposure, a negative 3rd generation HIV ELISA Test "would definitively exclude HIV infection."
HIV symptoms which may present in acute HIV infection: These are nonspecific symptoms and can present with other infections; consequently, they are unreliable indicators of HIV infection.
Remember, there is no HIV cure.
HIV ELISA (Enzyme-linked immunosorbent assay) test generations:
References HIV rapid test (20 minutes to results) Two types are available:
- 1st generation: HIV-1 IgG antibody
- 2nd generation: HIV-1 & HIV-2 IgG antibodies
- 3rd generation: HIV-1 & HIV-2 IgG & IgM antibodies
- 4th generation: HIV-1 & HIV-2 IgG & IgM antibodies and HIV p24 antigen
Note: If the clinic attendance is only for the HIV rapid test, then consultation fees are not added.
References HIV PCR (polymerase chain reaction) NAT (nucleic acid test) HIV Risk (2009 figures)
Estimated HIV transmission risk per exposure for specific activities and events
|Activity ||Risk-per-exposure |
|Vaginal sex, female-to-male, studies in high-income countries ||0.04% (1:2380) |
|Vaginal sex, male-to-female, studies in high-income countries ||0.08% (1:1234) |
|Vaginal sex, female-to-male, studies in low-income countries ||0.38% (1:263) |
|Vaginal sex, male-to-female, studies in low-income countries ||0.30% (1:333) |
|Vaginal sex, source partner is asymptomatic ||0.07% (1:1428) |
|Vaginal sex, source partner has late-stage disease ||0.55% (1:180) |
|Receptive anal sex amongst gay men, partner unknown status ||0.27% (1:370) |
|Receptive anal sex amongst gay men, partner HIV positive ||0.82% (1:123) |
|Receptive anal sex with condom, gay men, partner unknown status ||0.18% (1:555) |
|Insertive anal sex, gay men, partner unknown status ||0.06% (1:1666) |
|Insertive anal sex with condom, gay men, partner unknown status ||0.04% (1:2500) |
|Receptive fellatio ||Estimates range from 0.00% to 0.04% (1:2500) |
|Mother-to-child, mother takes at least two weeks antiretroviral therapy ||0.8% (1:125) |
|Mother-to-child, mother takes combination therapy, viral load below 50 ||0.1% (1:1000) |
|Injecting drug use ||Estimates range from 0.63% (1:158) to 2.4% (1:41) |
|Needlestick injury, no other risk factors ||0.13% (1:769) |
|Blood transfusion with contaminated blood ||92.5% (9:10) |
Sources: vaginal sex;1 anal sex;2 fellatio;3 2 mother-to-child;4 other activities.5
- Boily MC et al. Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis 9(2): 118-129, 2009
- Vittinghoff E et al. Per-contact risk of human immunodeficiency virus transmission between male sexual partners. American Journal of Epidemiology 150: 306-311, 1999
- Del Romero J et al. Evaluating the risk of HIV transmission through unprotected orogenital sex. AIDS 16(9): 1296-1297, 2002
- Townsend C et al. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS 22: 973-981, 2008
- Baggaley RF et al. Risk of HIV-1 transmission for parenteral exposure and blood transfusion. AIDS 20: 805-812, 2006
- HIV & AIDS Information :: How transmission occurs - Estimated risk per exposure
HIV Risk (2005 figures)
Estimated per-act risk for acquisition of HIV, by exposure route*
*Estimates of risk for transmission from sexual exposures assume no condom use.
|Exposure route||Risk per 10,000|
to an infected source
|Needle-sharing injection-drug use||67||0.67|
|Receptive anal intercourse||50||0.5|
|Percutaneous needle stick||30||0.3|
|Receptive penile-vaginal intercourse||10||0.1|
|Insertive anal intercourse||6.5||0.065|
|Insertive penile-vaginal intercourse||5||0.05|
|Receptive oral intercourse†||1||0.01|
|Insertive oral intercourse†||0.5||0.005|
†Source refers to oral intercourse performed on a man.
HIV risk (2002 figures)
HIV Risk Statistics (chances of getting HIV)
|HIV Risk Factors ||HIV Transmission Probability |
|Needle stick injury3 ||1/300 |
|Receptive anal intercourse4 ||1/100 |
|Receptive vaginal intercourse5 ||1/1000 |
|Insertive vaginal intercourse4 ||1/2000 |
|Insertive anal intercourse4 ||1/2500 |
|Receptive fellatio with ejaculation4 ||1/2500 |
|Sharing needles6 ||1/150 |
HIV prevention / HIV PEP (post-exposure prophylaxis) treatment can prevent you from getting an HIV infection, and turning HIV positive.
- Cardo DM, Culver DH, Ciesielski CA, et al. A Case-Control Study of HIV Seroconversion in Health Care Workers after Percutaneous Exposure. N Engl J Med. 1997;337:1485-1490.
- Katz MH, Gerberding JL. Management of occupational and nonoccupational postexposure HIV prophylaxis. Current Inf Dis Reports. 2002;4:543-549.
- Gerberding JL. Prophylaxis for Occupational Exposure to HIV. Ann Intern Med. 1996;6:497-501
- Vitinghoff E, Douglas J, Judon F, et al. Per-Contact Risk of Human Immunodificiency Virus Transmision between Male Sexual Partners. Am J Epidemiol. 1999;150:306-311.
- Peterman TA, Stoneburner RL, Allen JR, et al. Risk of Human Immunodeficiency Virus Transmission From Heterosexual Adults With Transfusion-Associated Infections. JAMA. 1988;259:55-58. [Erratum. JAMA. 1989;262:502]
- Kaplan EH, Heimer R. A Model-Based Estimate of HIV Infectivity via Needle Sharing. J Acquir Immune Defic Syndr. 1992;5:1116-1118.
Individuals are eligible for HIV PEP Treatment if all the following criteria are met:
Prompt antiviral therapy may reduce the risk of HIV transmission by as much as 80%.
- less than 72 hours has elapsed since exposure;
- the exposed individual is not known to be HIV infected;
- the person who is the source of exposure is HIV infected or has unknown HIV status;
- mucous membrane or non-intact skin was exposed to a potentially infectious body fluid;
For optimal efficacy, antiretroviral therapy should be started as soon as possible, ideally within 1 hour of exposure. So that you can remain HIV negative.
The medications and dosages are the same as those used for lifelong treatment of HIV patients. However, for HIV PEP treatment, it is taken for only a month.
References Drugs commonly used in HIV PEP: References TORCH
(of HIV/STD/pregnancy), and what you can do before and after exposure.
Innovaacom to Offer Courses on Grantsmanship for International...
Fri, 30 Jan 2015 06:05:04 +0100 | PRWeb: Medical Pharmaceuticals
New Innovaacom Grant Writing Continuing Education Course Aids Physicians and Scientists Applying for Medical Science Grants in Improving Submission Success Rates(PRWeb January 29, 2015)Read the full story at http://www.prweb.com/releases/2015/01/prweb12478303.htm (Source: PRWeb: Medical Pharmaceuticals)
Evotaz Combo Pill Approved for HIV-1 in AdultsEvotaz Combo Pill Approved for HIV-1 in Adults
Fri, 30 Jan 2015 03:19:55 +0100 | Medscape Medical News Headlines
The FDA has approved atazanavir and cobicistat (Evotaz) for treatment of adults with human immunodeficiency virus (HIV-1) infection. FDA Approvals (Source: Medscape Medical News Headlines)
Active Bone Conduction System: Outcomes with the Bonebridge Transcutaneous Device
Fri, 30 Jan 2015 01:16:58 +0100 | ORL
Conclusions: The BB device is a safe and effective solution for individuals with pathologies such as chronic otitis media, atresia auris and otosclerosis with inadequate benefit from conventional surgery or bone conduction hearing aids.ORL 2015;77:17-26 (Source: ORL)
Disseminated Emmonsia in an HIV-HBV co-infected man
Fri, 30 Jan 2015 00:00:00 +0100 | IDCases
We describe a patient with several co-morbidities and an unusual disseminated fungal infection. (Source: IDCases)
Questionnaire ABEL - Auditory Behavior in Everyday Life: a study of reliability - internal consistency of the brazilian version and reproducibility for test-retest
Thu, 29 Jan 2015 14:21:10 +0100 | Revista CEFAC
CONCLUSIONS: the Portuguese version of ABEL showed reliability - reproducibility and internal consistency. There is an association between the degree of hearing loss and scores on specific items and in Auditory Awareness Factor. There is an association between interviewee's schooling and the score in item "Asks for help in situations where it is needed". (Source: Revista CEFAC)
The use of self-assessment questionnaires for validation of the results in hearing aid selection and fitting process
Thu, 29 Jan 2015 14:21:10 +0100 | Revista CEFAC
CONCLUSION: by applying the questionnaire, it was found that the hearing aid use has benefic effects for their users and that they were satisfied with it. (Source: Revista CEFAC)
HIV Transmission Risk Behaviors Among People Living With HIV/AIDS: The Need to Integrate HIV Prevention Interventions and Public Health Strategies Into HIV Care
Thu, 29 Jan 2015 14:16:10 +0100 | Journal of Public Health Management and Practice
Conclusions: High-risk sexual behaviors are commonly reported by PLWHA, and these behaviors may be influenced by their partners' characteristics. HIV prevention interventions and public health strategies need to be incorporated into HIV care. (Source: Journal of Public Health Management and Practice)
Aqua-Chem Aids Department of Defense in Containing Ebola Virus...
Thu, 29 Jan 2015 10:00:11 +0100 | PRWeb: Medical Pharmaceuticals
Aqua-Chem, Inc., a worldwide leader in manufacturing water purification systems, is supporting the Department of Defense's efforts to contain the Ebola virus in western Africa.(PRWeb January 28, 2015)Read the full story at http://www.prweb.com/releases/2015/01/prweb12470814.htm (Source: PRWeb: Medical Pharmaceuticals)
Botswana: HIV, Aids Remains Ministry's Priority
Thu, 29 Jan 2015 09:34:17 +0100 | AllAfrica News: HIV-Aids and STDs
[Botswana Daily News]Gaborone -Permanent secretary in the Ministry of Health, Dr Kolaatamo Malefho has called on Batswana to behave well and practice safe sex in order to stop the spread of HIV/ AIDS. (Source: AllAfrica News: HIV-Aids and STDs)
Nigeria: NACA, SURE-P to Embark on HIV Counselling in IDPs in Three States
Thu, 29 Jan 2015 09:17:04 +0100 | AllAfrica News: HIV-Aids and STDs
[Guardian]Abuja -THE National Agency for the Control of AIDS (NACA) and the Subsidy Re-investment and Empowerment Programme (SURE-P) have covered seven states as part of their national HIV counselling and testing campaign. (Source: AllAfrica News: HIV-Aids and STDs)